皮下免疫治疗安全性的研究进展

Progress on safety of subcutaneous immunotherapy

过敏性疾病是一类常见的慢性病,其治疗周期长、易反复,给全球造成了沉重的医疗和经济负担。过敏原特异性免疫治疗(allergen immunotherapy,AIT)是IgE介导的过敏性疾病的对因疗法,可改变过敏性疾病的进程。虽然大量的临床研究已证实AIT在治疗过敏性疾病中的有效性与安全性,但严重甚至致死性的不良反应仍有发生,尤其是在皮下免疫治疗(subcutaneous immunotherapy,SCIT)过程中。该文主要关注了SCIT安全性的最新研究进展,综述了SCIT不良反应的研究现状、危险因素、应对措施以及未来研究方向。

Allergic diseases are a kind of common chronic diseases,whose treatment cycle is long and easy to be repeated,which causes heavy medical and economic burden to the whole world.Allergen immunotherapy(AIT)is the cause-specific therapy for IgE mediated allergic diseases and can change the course of allergic diseases.Although numerous clinical studies have demonstrated the efficacy and safety of AIT in the treatment of allergic diseases,severe and even fatal adverse reactions still occur,especially in subcutaneous immunotherapy(SCIT).This review mainly focuses on the latest research progress of SCIT safety,and summarizes the research status,risk factors,countermeasures and future research directions of SCIT adverse reactions.